Everolimus

Specimen Tube Type Transport

Lavender Top Tube

Container Whole Blood Required

3 ml whole blood in a Lavender (EDTA) Top

Summary Test Name

Everolimus

Specimen Preparation Outreach

Refrigerate until courier pickup

Specimen Stability

Ambient: 24 hours; Refrigerated: 2 weeks; Frozen: 2 weeks

Minimum Volume

0.25 mL whole blood in (2) Lavender Top Microtainers

Specimen Transport

Refrigerate

Specimen Preparation In House

Refrigerate until transport

Stat Availability

Not available STAT

Test Turnaround Time Routines And Stats

Samples received by 0700 Monday - Saturday will be sent by courier tp ARUP

Reference Value

Everolimus marketed as Afinitor is FDA approved for the treatment of renal cell carcinoma and for the treatment of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS) in patients who are not candidates for curative surgical resection. The suggested therapeutic range for treatment of SEGA is 5-15 ng/mL, which is based on a predose (trough) specimen.

The optimal therapeutic range for a given patient may differ from this suggested range based on the indication for therapy, treatment phase (initiation or maintenance), use in combination with other drugs, time of specimen collection relative to prior dose, type of transplanted organ, and/or the therapeutic approach of the transplant center.

Effective February 18, 2014

	Therapeutic Range:
Kidney transplant (in combination with Cyclosporine):	3-8 ng/mL
Liver transplant (in combination with Tacrolimus):	3-8 ng/mL
Toxic value:	Greater than 15 ng/mL

Note:

Everolimus (Zortress, Certican, Afinitor) whole blood concentrations can be measured by either chromatographic or immunoassay methodologies.  These two methodologies are not directly interchangeable, and the measured everolimus whole blood concentration depends on the methodology used, and reference ranges may vary according to specific immunoassay or HPLC/MS/MS test. Generally, immunoassays have been reported to have a positive test bias relative to HPLC-MS/MS assays, due to the detection of antibody cross-reactivity with everolimus metabolites.